Identifying Immune-related Biomarkers to Predict the Efficacy of Cancer Immunotherapy (IMMUNO-SUP)

Institut Paoli-Calmettes

Status

Active, not recruiting

Conditions

Locally Advanced Malignant Neoplasm

Lung Cancer Metastatic

Non Hodgkin Lymphoma

Urologic Neoplasms

Treatments

Procedure: Blood sample collection

Procedure: Biopsy collection

Study type

Interventional

Funder types

Other

Identifiers

NCT03595813

IMMUNO-SUP-IPC 2017-002

Details and patient eligibility

About

The development of Immune Checkpoint Blockade (ICB) is a revolution in medical oncology as ICB have changed the standard treatments of several metastatic tumor types. However, the response rate to ICB is low, and the biological bases for this response heterogeneity are poorly understood.

In the frame of Immunosup study, we will collect blood (at baseline, post infusion of ICB n°2/4/8 and at progression) and tumor samples (optional: at baseline and progression) from patients with locally advanced or metastatic cancer, treated with ICB, in order to determine if the dynamics of immunosuppressive actors (MDSC, TReg, Immunosuppressive cytokines) predicts response to these immunotherapies.

Enrollment

135 patients

Sex

All

Ages

18+ years old

Volunteers

No Healthy Volunteers

Inclusion criteria

Age > 18 years
Diagnosis of locally advanced or metastatic solid tumor or lymphoma treated with Immune check blockade
Signed informed consent
Affiliated to(or beneficiary of) the French Social Security

Exclusion criteria

Pregnant or breastfeeding woman or woman who does not apply effective contraception
Emergency
Vulnerable person or unable to provide informed consent
Emergency
Person unable to comply with required study follow up
Contraindication to the study procedure